CARDIOMECH
CardioMech is a developer of therapeutic devices for structural heart disease that provides a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve. The company's devices are used for the placement of artificial chords, enabling surgeons to get access to new therapeutic options for heart diseases. The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail. CardioMech was founded in 2015 and is headquartered in Trondheim, Norway.
CARDIOMECH
Social Links:
Industry:
Biotechnology Health Care Medical Medical Device
Founded:
2015-01-01
Address:
Trondheim, Sor-Trondelag, Norway
Country:
Norway
Website Url:
http://www.cardiomech.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
37.19 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Content Delivery Network Google Universal Analytics GStatic Google Static Content Amazon S3 Amazon SSL Amazon CloudFront
Similar Organizations
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Dyne Therapeutics
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Gracell Biotechnologies
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Investinor
Investinor investment in Series A - CardioMech
Hadean Ventures
Hadean Ventures investment in Series A - CardioMech
Official Site Inspections
http://www.cardiomech.com
- Host name: bristol.domeneshop.no
- IP address: 194.63.248.52
- Location: Norway
- Latitude: 59.9452
- Longitude: 10.7559
- Timezone: Europe/Oslo
More informations about "CardioMech"
CardioMech - Crunchbase Company Profile & Funding
CardioMech is a developer of therapeutic devices for structural heart disease that provides a transcatheter alternative to cardiac surgery for the placement of …See details»
CardioMech 2025 Company Profile: Valuation, Funding …
CardioMech General Information Description. Developer of catheter-based technology designed to provide an alternative to open-heart cardiac surgery. …See details»
CardioMech - Products, Competitors, Financials, Employees, …
About CardioMech. CardioMech develops therapeutic solutions for heart disease in the healthcare and medical technology sectors. The company's main offering is a catheter-based mitral valve …See details»
CardioMech Snags $13M For Its Mitral Valve Repair Tech
Jan 3, 2024 Medical device startup CardioMech announced this week that it has raised $13 million in new capital, bringing its total funding to $42 million. With the fresh funds, the company hopes to advance ...See details»
Press release Jan.2.2024 - Cardiomech
About CardioMech AS. Headquartered in Oslo, Norway, CardioMech AS is a privately held company that is developing a transcatheter alternative to cardiac surgery for the placement of …See details»
CARDIOMECH RAISES $13M IN HEAVILY OVERSUBSCRIBED …
Jan 2, 2024 About CardioMech: CardioMech AS, a privately held company, is developing its transcatheter mitral valve chordal repair technology. Caution: Investigational device. Limited …See details»
CardioMech - Funding, Financials, Valuation & Investors
CardioMech develops devices for structural heart disease, offering alternatives to cardiac surgery, specifically for mitral valve issues. New. Resources. ... How much funding has this …See details»
CardioMech Company Profile - Office Locations, Competitors
CardioMech has 5 employees at their 1 location and $23.5 m in total funding,. See insights on CardioMech including office locations, competitors, revenue, financials, executives, …See details»
CardioMech Company Information - Funding, Investors, and More
Key Insights: CardioMech January 2024 Series A Funding Round: $13m CardioMech Funding Round, April 2022: $6.17m CardioMech August 2020 Series A Funding Round: $19m …See details»
CardioMech - Contacts, Employees, Board Members, Advisors
CardioMech develops devices for structural heart disease, offering alternatives to cardiac surgery, specifically for mitral valve issues.See details»
Medical device company raises $13M for new mitral valve repair …
Jan 2, 2024 CardioMech sees the device as an opportunity to treat younger, healthier patients who present with severe MR without performing open heart surgery. The funding round …See details»
CardioMech Expands Mitral Leadership Team - Medical Product …
Apr 30, 2019 “CardioMech is participating in one of the most innovative segments of medicine with a significant unmet need,” she said. Groenewegen is co-founder and managing director of …See details»
CardioMech Raises $13M in Funding - FinSMEs
Jan 2, 2024 CardioMech AS, a Trondheim, Norway-based medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology, raised $13M in …See details»
Investors offer backing for developer of transcatheter mitral chord ...
Jan 2, 2024 Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, USA, …See details»
CardioMech Company Information - Funding, Investors, and More
The company CardioMech has raised a total of $15.5m in funding over 2 rounds. Key Insights: Series A: $13m; Unknown: $2.5m; 2019. CardioMech Unknown (2019, $2M) $2.5m. 2024. …See details»
CardioMech Raises $13 Million for Transcatheter Mitral Chordal …
Jan 8, 2024 CardioMech AS (“CardioMech”) announced that the company successfully raised $13 Million in capital in addition to the $18.5 Million Series A financing in 2020 bringing total …See details»
CardioMech AS Announces $18.5M Series A for its Transcatheter …
Aug 6, 2020 The Series A, led by a non-disclosed strategic investor, together with Hadean Ventures and Investinor, will fund CardioMech’s journey to treat patients in a first-in-human …See details»
CardioMech Raises $13M in Heavily Oversubscribed Round for its ...
Jan 2, 2024 CardioMech received strong support by investors despite challenging environment because of its potential to be a category-defining Chordal Repair technology MINNEAPOLIS, …See details»
Norwegian CardioMech Raises $13M for ... - G-MedTech News …
Aug 21, 2023 The CardioMech device is an artificial chord that is designed to reduce or eliminate regurgitation and to restore the native anatomy. Skip to content. All News. Latest …See details»